Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Guilherme, Nader Marta"'
Autor:
Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino, Evandro de Azambuja, Georg Pfeiler, Miguel Martin, Justin M. Balko, Zbigniew Nowecki, Marija Balic, Adam M. Brufsky, Arlene Chan, Patrick G. Morris, Tufia Haddad, Sibylle Loibl, Yuan Liu, Lidija Soelkner, Christian Fesl, Erica L. Mayer, Michael Gnant, on behalf of the PALLAS groups and investigators
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive biomarker in patients w
Externí odkaz:
https://doaj.org/article/c4f4965043a847fba7a786c64cdbe554
Publikováno v:
Breast, Vol 74, Iss , Pp 103700- (2024)
The results of several studies aiming to tailor early breast cancer treatment to individual risk were released in 2023. Axillary lymph node dissections and radiotherapy may be safely omitted in carefully selected patients. Sustained benefit from adju
Externí odkaz:
https://doaj.org/article/c94d6be8271a4c799fdeb8f0b6c0fe2b
Autor:
Martine Piccart-Gebhart, Emanuela Romano, Christos Sotiriou, Marianne Paesmans, Ligia Craciun, Denis Larsimont, Roberto Salgado, Elisa Agostinetto, Laurence Buisseret, Isabelle Veys, Alex de Caluwé, Philip Poortmans, Andrea Gombos, Guilherme Nader Marta, Zoe Denis, Stylianos Drisis, Christophe Vandekerkhove, Antoine Desmet, Catherine Philippson, Dirk Van Gestel, Michail Ignatiadis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Background Luminal B breast cancer (BC) presents a worse prognosis when compared with luminal A BC and exhibits a lower sensitivity to chemotherapy and a lower immunogenicity in contrast to non-luminal BC subtypes. The Neo-CheckRay clinical trial inv
Externí odkaz:
https://doaj.org/article/a5ee6654546a4d7e98521bceca85490a
Autor:
Guilherme Nader-Marta, Chiara Molinelli, Véronique Debien, Diogo Martins-Branco, Philippe Aftimos, Evandro de Azambuja, Ahmad Awada
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Antibody–drug conjugates (ADCs) are a class of antineoplastic agents whose structure is composed of three main components: a monoclonal antibody (mAB) targeting a specific target antigen, a cytotoxic payload, and a linker binding the antibody to th
Externí odkaz:
https://doaj.org/article/7a5ff39dd5c6423c93c2492ba0e8da2b
Autor:
Guilherme Nader Marta, Renata Colombo Bonadio, Odeli Nicole Encinas Sejas, Gabriel Watarai, Maria Cecilia Mathias Machado, Lorena Teixeira Frasson, Camila Motta Venchiarutti Moniz, Raquel Keiko de Luca Ito, Driele Peixoto, Camilla Oliveira Hoff, Veruska Menegatti Anastacio, Ulysses Ribeiro, Juliana Pereira, Vanderson Rocha, Edson Abdala, Maria Del Pilar Estevez-Diz, Paulo M. Hoff
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 1084-1092 (2021)
PURPOSEPatients with cancer are at increased risk for unfavorable outcomes from COVID-19. Knowledge about the outcome determinants of severe acute respiratory syndrome coronavirus 2 infection in this population is essential for risk stratification an
Externí odkaz:
https://doaj.org/article/e2217bc45bc8429d921404f56a00323a
Autor:
Rodrigo Ramella Munhoz, Clarissa Maria de Cerqueira Mathias, Guilherme Harada, Aknar Calabrich, Alberto Julius Wainstein, Andréia Cristina de Melo, Antonio Carlos Buzaid, Artur Katz, Carlos Gil Ferreira, Carlos Henrique dos Anjos, Clarissa Baldotto, Elimar Elias Gomes, Fernando Moura, Gilberto de Castro, Guilherme Nader Marta, Gustavo dos Santos Fernandes, Luiza Dib Batista Bugiato Faria, Mariana Laloni, Paulo Marcelo Gehm Hoff, Romualdo Barroso-Sousa, Sergio Jobim de Azevedo, Vladmir Cláudio Cordeiro de Lima, William Nassib William
Publikováno v:
Brazilian Journal of Oncology, Vol 18, Iss 00 (2022)
Immunotherapy (IT) in the form of monoclonal antibodies targeting coreceptors involved in the modulation of the immune synapse represents a standard of care for patients with distinct malignancies. Over the past years, evidences supporting the clinic
Externí odkaz:
https://doaj.org/article/d7a25db8b1ed454ebec29e265ba0d6dd
Autor:
Gustavo Nader Marta, Tomás Y. T. de Souza, Alice R. N. de Souza e Silva, Ana Paula A. Pereira, David R. Ferreira Neto, Rie N. Asso, Fabiana A. M. Degrande, Guilherme Nader-Marta, Maurício F. da Silva, Rafael Gadia, Samir A. Hanna, Bernhard Holzner, Everardo D. Saad, Morten Aagaard Petersen
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3373-3383 (2021)
Background: This study aimed to validate the Brazilian version of EORTC CAT Core and compare the Brazilian results with those from the original European EORTC CAT Core validation study. Methods: After validated translation, 168 cancer patients from B
Externí odkaz:
https://doaj.org/article/25d9e3bb8cd0479680ff2f4b0be563fa
Autor:
Guilherme Nader Marta, Rodrigo Ramella Munhoz, Monica La Porte Teixeira, Bernadette Cunha Waldvogel, Veridiana Pires de Camargo, Olavo Feher, Jose Antonio Sanches
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 1766-1771 (2020)
PURPOSEA substantial increase in melanoma incidence has been consistently observed worldwide over the past decades. However, melanoma mortality rates have remained stable or declined over the past years in most regions. Given the paucity of melanoma
Externí odkaz:
https://doaj.org/article/8998384dcc3b4108ae5a2be17e30c5ab
Autor:
Guilherme Nader Marta, Leonardo G. da Fonseca, Maria Ignez Braghiroli, Fernando Moura, Paulo M. Hoff, Jorge Sabbaga
Publikováno v:
Clinics, Vol 76 (2021)
OBJECTIVES: To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC). METHODS: We analyzed data from a cohort of patients with advanced HCC treated using systemic treatment according to the loc
Externí odkaz:
https://doaj.org/article/95db7a37cf154a989acb8cc5cdbfe5d6
Autor:
Diogo Martins-Branco, Chiara Molinelli, Guilherme Nader Marta, Lieveke Ameye, Marianne Paesmans, Roberto Salgado, Philippe Aftimos, Evandro de Azambuja
Publikováno v:
Cancer Research. 83:P1-07
Background: Neoadjuvant treatment allows to better distinguish responders from non-responders, and to tailor post-neoadjuvant treatment according to tumor response in patients with HER2+ and triple-negative early breast cancer. For HR+/HER2- tumors,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a1a157545c167fffadac0f3e9288d03
https://doi.org/10.1158/1538-7445.sabcs22-p1-07-01
https://doi.org/10.1158/1538-7445.sabcs22-p1-07-01